ClinicalTrials.Veeva
Menu

Find clinical trials for Endometrial Cancer in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Ovarian Cancer
Breast Cancer
Carcinoma
Triple Negative Breast Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Endometrial Cancer trials near Barcelona, CT, ESP:

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain (DUoENDE)

This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclit...

Active, not recruiting
Advanced or Recurrent Endometrial Cancer
Drug: Durvalumab + Chemotherapy phase
Drug: Durvalumab + Olaparib phase

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 24 other locations

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to p...

Enrolling
Endometrial Cancer
Malignant Solid Tumour
Drug: Doxorubicin
Drug: Puxitatug Samrotecan

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 153 other locations

for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...

Active, not recruiting
Endometrial Cancer
Drug: Matching placebo for selinexor
Drug: Selinexor

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Barcelona, Spain and 77 other locations

study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial...

Active, not recruiting
Endometrial Cancer
Drug: Carboplatin-Paclitaxel
Drug: Dostarlimab

Phase 3

ARCAGY/ GINECO GROUP

Badalona, Spain and 94 other locations

(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...

Active, not recruiting
Endometrial Neoplasms
Drug: Carboplatin
Biological: durvalumab

Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 202 other locations

Locations recently updated

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when com...

Enrolling
Endometrial Cancer
Drug: Carboplatin
Drug: Paclitaxel

Phase 3

AstraZeneca
AstraZeneca

L'Hospitalet de Llobregat, Spain and 242 other locations

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Nab-paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Barcelona, Spain and 243 other locations

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...

Enrolling
Endometrial Cancer
Drug: Navtemadlin
Drug: Navtemadlin Placebo

Phase 2, Phase 3

Kartos Therapeutics
Kartos Therapeutics

Barcelona, Spain and 82 other locations

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer...

Enrolling
Endometrial Cancer
Drug: Paclitaxel
Drug: Sacituzumab govitecan-hziy

Phase 3

Gilead Sciences
Gilead Sciences

Barcelona, Spain and 186 other locations

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advance...

Enrolling
Endometrial Cancer
Drug: Carboplatin
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

L'Hospitalet de Llobregat, Barcelona, Spain and 84 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems